<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633798</url>
  </required_header>
  <id_info>
    <org_study_id>SHAIER2020IRB04</org_study_id>
    <nct_id>NCT04633798</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction</brief_title>
  <official_title>Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aier School of Ophthalmology, Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aier School of Ophthalmology, Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of IPL combined with lipiflow and IPL combined with meibomian gland&#xD;
      massage in treating meibomian gland dysfunction of different degrees ,focusing on effective&#xD;
      rate, lasting time and changes of meibomian gland function and morphology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To divide all participants into two groups, group one treated with IPL combined with Lipiflow&#xD;
      and group two treated with IPL combined with meibomian gland massage.The following parameters&#xD;
      were recorded after treatment: the effective rate, lasting time and changes of meibomian&#xD;
      gland function and morphology.All parameters were compared between the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ocular surface disease index(OSDI)</measure>
    <time_frame>6 months</time_frame>
    <description>The OSDI is assessed on a scale of 0 to 100,with higher scores representing greater disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland expressibility score and meibum quality score</measure>
    <time_frame>6 months</time_frame>
    <description>The score is on a scale of 0 to 6.The higher scores, the severity of the meibomian gland function(the highest score is 6 and the lowest score is 0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland dropout score</measure>
    <time_frame>6 months</time_frame>
    <description>the higher scores, the severity of the meibomian gland morphology(The highest score is 6 and the lowest score is 0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breakup time</measure>
    <time_frame>6 months</time_frame>
    <description>the shorter time, the poorer of the tear film stability</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>IPL/Lipiflow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the group in which patients treated with IPL combined with lipiflow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPL/MGX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the group in which patients treated with IPL combined with meibomian gland massage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPL/Lipiflow</intervention_name>
    <description>To treat patients with MGD using intense pulsed light combined with lipiflow</description>
    <arm_group_label>IPL/Lipiflow</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPL/MGX</intervention_name>
    <description>To treat patients with MGD using intense pulsed light combined with meibomian gland massage</description>
    <arm_group_label>IPL/MGX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with meibomian gland dysfunction&#xD;
&#xD;
          -  patients with ocular discomfort&#xD;
&#xD;
          -  skin type:FitzpatricⅠ-Ⅳ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with acute ocular inflammation&#xD;
&#xD;
          -  eye surgery history in the last 12 months&#xD;
&#xD;
          -  patients who have received IPL or Lipiflow in the last 12 months&#xD;
&#xD;
          -  patients who wear contact lens in last one month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Chen, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai aier eys hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Chen, doctor</last_name>
    <phone>+86-021-62956699</phone>
    <email>chinacy@hotmail.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

